ESMO

Significant survival gain with fruquintinib in patients with heavily pretreated disease

"Encouraging activity" with enfortumab vedotin-pembrolizumab in patients with high unmet need

However, no benefit seen with short-term hormone therapy versus radiotherapy alone

Large increase in event-free survival with neoadjuvant plus adjuvant versus only adjuvant therapy

"New second-line standard" in KRAS G12C-mutant disease, says study investigator

Randomized study shows "clinically meaningful" PFS improvement over dual immunotherapy alone

Atezolizumab doubles OS at 2 years versus chemotherapy in those ineligible for platinum doublets

Pathologic complete responses seen in 63% of patients in phase II data

Studies appear to contradict benefit previously shown with pembrolizumab in this setting

About half of patients responded to tepotinib plus osimertinib, but efficacy ceiling persists

Preoperative immunotherapy combo in dMMR disease yields major pathologic response in 95%

More than 50% increase in 6-month PFS versus ipilimumab after progression on first-line anti-PD-1

Post hoc data point to possible benefit in patients with higher PD-L1 levels

Study also shed lights on what may lead to lung cancer in never smokers